Intradiscal methylene blue injection for the treatment of chronic discogenic low back pain

What Was Tested

This clinical trial paper looks at Methylene blue (non-peptide stack partner) in the context of chronic pain: fibromyalgia & crps.

Twenty-four patients with chronic discogenic low back pain underwent diagnostic discography with intradiscal injection of MB.

The mean follow-up period was 18.2 months (range 12-23 months).

Who Took Part

The study group was 24 patients.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

This article was a preliminary report of prospective clinical trial of a group of patients with chronic discogenic low back pain who met the criteria for lumbar interbody fusion surgery but were treated instead with an intradiscal injection of methylene blue (MB) for the pain relief.

What Was Measured

PubMed files the paper under topics including Analgesics, Benzenesulfonates, Chronic Disease, Injections, Spinal, Low Back Pain and Pain Measurement.

What This Means in Plain Language

This is a clinical trial of Methylene blue (non-peptide stack partner) in 24 patients in people with chronic pain: fibromyalgia & crps.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2007 (European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society), a journal based in Germany.

More context: the Methylene blue (non-peptide stack partner) compound page, Chronic pain: fibromyalgia & CRPS research.